Arun B. Jesudian, MD: Thank you for joining us for this unique AJMC®, MD Magazine®, and Pharmacy Times Peer Exchange titled “Chronic Liver Disease and Improved Outcomes in the Management of Hepatic ...
Rifaximin improves the gut microenvironment by reducing the abundance of harmful bacteria while increasing probiotic bacteria. It inhibits the translocation of bacteria from the mouth to the intestine ...
Please provide your email address to receive an email when new articles are posted on . Montagnese and colleagues identified patients with Child-Pugh A/B cirrhosis and abnormal continuous reaction ...
ACG published its first complete guideline on the diagnosis and management of hepatic encephalopathy, with practical tools ...
Roughly half as many patients with cirrhosis in remission from overt hepatic encephalopathy (OHE) experienced a breakthrough episode with rifaximin monotherapy compared with lactulose monotherapy, a ...
Urease-positive Streptococcus salivarius was the most significantly abundant gut microbiota in patients with HE. Certain gut microbiota are strongly associated with the pathophysiology of hepatic ...
Intestinal failure–associated liver disease (IFALD) is a major concern in the management of pediatric intestinal failure, representing a leading cause of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results